search
Back to results

The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms

Primary Purpose

Mild Traumatic Brain Injury, Concussion, Brain

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Creatine Monohydrate
Sponsored by
Psychiatric Research Unit, Region Zealand, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Mild Traumatic Brain Injury focused on measuring Concussion, Mild traumatic brain injury, Creatine monohydrate, Persistent post-concussive symptoms

Eligibility Criteria

25 Years - 35 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have had PPCS for a minimum of six months and a maximum of 12 months at the start of the study.
  • Being between 25 and 35 years of age

Exclusion Criteria:

  • Elite athletes, as well as people who in general is physical active for more than ten hours a week on average.
  • Participation in other interventions/treatment than this study
  • Have had PPCS in:
  • <6 months
  • >12 months
  • Pregnant
  • Other brain diseases or traumatic injuries
  • Musculoskeletal diseases

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    No Intervention

    Placebo Comparator

    Arm Label

    Intervention group

    Control group

    Placebo

    Arm Description

    Creatine monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.

    The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature. In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.

    Powdered Sugar administered once a day for seven weeks - with 5g/day for the entire period.

    Outcomes

    Primary Outcome Measures

    Change from Baseline Post-Concussion Symptoms at 7 weeks
    Rivermead Post-Concussion Symptom Questionnaire

    Secondary Outcome Measures

    Change from Baseline Body weight at 7 weeks
    As we are using a dietary supplement as our intervention, following participants body weight in kg throughout the intervention is necessary in order to know if changes in body weight have any effect on our results.

    Full Information

    First Posted
    September 14, 2022
    Last Updated
    September 27, 2022
    Sponsor
    Psychiatric Research Unit, Region Zealand, Denmark
    Collaborators
    University of Southern Denmark
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05562232
    Brief Title
    The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms
    Official Title
    The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms - a Pilot Study Protocol
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 1, 2022 (Anticipated)
    Primary Completion Date
    November 30, 2022 (Anticipated)
    Study Completion Date
    January 31, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Psychiatric Research Unit, Region Zealand, Denmark
    Collaborators
    University of Southern Denmark

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study, is to investigate whether creatine monohydrate as a supplement reduces the number and severity of symptoms in patients with persistent post-concussive symptoms through self-reported post-concussion symptoms questionnaires.
    Detailed Description
    Mild traumatic brain injury (mTBI), which throughout the literature is used interchangeably with concussion, is a problem the media is drawing more and more attention to, which have made it a public concern too. It is estimated that between 0.6 % and 1.2 % of the general population will suffer an mTBI each year. Out of these, an estimated 10-30 % of the patients, will suffer from persistent post-concussive symptoms (PPCS). These symptoms typically includes headache, poor concentration, memory problems, fatigue, sleep difficulties, dizziness, irritability, feeling nervous or anxious. At the moment no single treatment option is available with guaranteed success, and therefore nutritional supplements are a possibility. The nutritional supplement Creatine Monohydrate (CrM) is one of the most popular ergogenic aids on the market among professional and amateur athletes. It is mostly used in the development of muscle mass, as creatine is primarily located skeletal muscle. Roughly five percent of the body's creatine is distributed in the brain and testicles. As mTBI's also see a change in the metabolism of the brain, creatine supplementation might be beneficial for patients with PPCS. This is further supported by a newly conducted study, that creatine supplementation may reduce the severity of mild concussion in animal models. Furthermore, as the enzyme Creatine Kinease (CK), which is involved in ATP energy system, also has a brain specific isoform (BB-CK), creatine may be a relevant part of the energy system of the central nervous system (CNS). In addition evidence points towards creatine supplementation can increase cellular energy availability. It has been reported to increase brain phosphocreatine content by as much as 15 %, which in turn improves the metabolic processes of the brain. CrM has been described to be a potent anti-inflammatory molecule. It has been shown to reduce the cytotoxic effects in oxidatively-injured cells without affecting antioxidant enzyme activities, and has been shown to inhibit reactive oxygen species-induced formation of mitochondrial permeability transition pores in the liver mitochondria of mice. At the same time, concussion seems to increase inflammation in the brain, and this inflammation has been hypothesized to correlate with the symptomatology and duration. And even though research in the area of recovery is still scarce, neuroinflammation seems to play a vital role in the pathophysiology of concussions. This warrants hopes of a decrease in post-concussive symptoms. Other studies have indicated an improvement of cognitive functions, including fatigue, working memory and mood state. All symptoms related to PPCS. Additionally evidence points towards creatine supplementation can help with chronic fatigue, depression and anxiety. All this points towards CrM being helpful in the treatment of PPCS. PPCS has proven to be not only a health problem, but also a socioeconomical problem. Data from Fallesen et al. showed that salary in Denmark five years after a concussion decreased 4.2 %, with an increased risk of losing ones job. Currently there is not viable treatment option for these patients, but if the intervention shows positive results, patients suffering from PPCS would be able to improve on their symptoms, relatively easy and cheap. They would have a go-to supplement, that would make it possible for them to get a normal day, without any of the symptoms connected to PPCS. The study will be performed as a randomized controlled study. The study is expected to include a convenience sample of 45 patients. The patients will randomly be allocated to either a control group (CG), placebo group (PLA) or intervention group (INT), with 15 patients in each. The study will be double blinded, i.e., the participants not knowing which group they will be allocated to. The study population consists of patients with persistent post-concussive symptoms between six and twelve months at start of participation. Participants will be recruited through social media and contact with neurological outpatient clinics throughout Denmark. At the start of the study, participants will have to be between 25 and 35 years of age. This will make the population a homogenous age group, and we will avoid physical and cognitive challenges related to early childhood and adolescents, as well as avoiding the degeneration in physical capacities that begin at approximately the age of 35 as well as the cognitive decline around the same time. Their anthropometrics will consist of: Age (years) Gender (male/female) Height (cm) Weight (kg) Period with PPCS (months) Concussion history (yes/no) If yes - how many (number) Training status (hours/week) Study procedure Baseline phase: Before inclusion in the study, participants have to sign a declaration of consent, to make them fully aware of what they agree to participate in, what risks there are and what they can gain from the study. When the declaration is signed, the participants have to have their height in cm and weight in kg measured, as well as answering how many concussions they previously suffered, along with their training status as hours/week. The baseline measurements concludes with participants answering the Rivermead Post-Concussion Symptom Questionnaire (RPQ). Study phase: The participants will randomly be allocated to either the CG, PLA or INT group. CG will not receive any treatment other than usual treatment. PLA and INT will both receive a powder, that has to be ingested. PLA will receive a powder similar in looks to CrM, but with no apparent nutritional value, while INT will receive CrM. oAs both PLA and INT are the interventions, they will follow the same protocol for ingestion 5 grams per day in seven weeks. All 5 grams will be ingested at once. This protocol has been chosen instead of the more common 0.3 g/day for the first week, ingested over five times during the day. In other studies on CrM and the brain, this have been the chosen strategy also. But studies on CrM in the muscles show, that both protocols illicit the same response with 28 days, and the loading phase is not required. Furthermore, some studies have used this protocol with creatine supplementation, and found increased cognitive function. Our reason for choosing 5 g/day in seven weeks, is to increase the chances of compliance, and decrease the risks of discomfort with to high an intake of CrM. An intake five times a day for the first week, is demanding, and will most likely get some participants to quit the study. At the mid phase of the study, all baseline measurements will be done again. End of study protocol: The length of the intervention is seven weeks. After the seven weeks, all baseline measurements will be done again. And a week after last ingestion, the measurements will be done one last time. At the week eight appointment, every participant will have to answer whether they thought they were getting placebo or CrM. This is done in order to figure out how big an effect placebo have on the results.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Mild Traumatic Brain Injury, Concussion, Brain
    Keywords
    Concussion, Mild traumatic brain injury, Creatine monohydrate, Persistent post-concussive symptoms

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    45 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention group
    Arm Type
    Experimental
    Arm Description
    Creatine monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.
    Arm Title
    Control group
    Arm Type
    No Intervention
    Arm Description
    The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature. In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Powdered Sugar administered once a day for seven weeks - with 5g/day for the entire period.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Creatine Monohydrate
    Intervention Description
    Follows
    Primary Outcome Measure Information:
    Title
    Change from Baseline Post-Concussion Symptoms at 7 weeks
    Description
    Rivermead Post-Concussion Symptom Questionnaire
    Time Frame
    Baseline, 3 weeks and 7 weeks (follow-up)
    Secondary Outcome Measure Information:
    Title
    Change from Baseline Body weight at 7 weeks
    Description
    As we are using a dietary supplement as our intervention, following participants body weight in kg throughout the intervention is necessary in order to know if changes in body weight have any effect on our results.
    Time Frame
    Baseline, 3 weeks and 7 weeks (follow-up)
    Other Pre-specified Outcome Measures:
    Title
    Height
    Description
    Descriptive measurement
    Time Frame
    Baseline
    Title
    Training status
    Description
    To determine if the participants are at the same initial training status.
    Time Frame
    Baseline
    Title
    Period with PPCS
    Description
    To assess persistent post-concussive symptoms
    Time Frame
    Baseline

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    25 Years
    Maximum Age & Unit of Time
    35 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Have had PPCS for a minimum of six months and a maximum of 12 months at the start of the study. Being between 25 and 35 years of age Exclusion Criteria: Elite athletes, as well as people who in general is physical active for more than ten hours a week on average. Participation in other interventions/treatment than this study Have had PPCS in: <6 months >12 months Pregnant Other brain diseases or traumatic injuries Musculoskeletal diseases
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ronni Lykke Bødker, MSc
    Phone
    +45 61710188
    Email
    ronni@commotio.dk
    First Name & Middle Initial & Last Name or Official Title & Degree
    Michael Marcussen, Dr.
    Phone
    +4526369503
    Email
    mhmarcussen@health.sdu.dk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Michael Marcussen, Dr.
    Organizational Affiliation
    University of Southern Denmark (SDU), Denmark
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    28446457
    Citation
    McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, Cantu RC, Cassidy D, Echemendia RJ, Castellani RJ, Davis GA, Ellenbogen R, Emery C, Engebretsen L, Feddermann-Demont N, Giza CC, Guskiewicz KM, Herring S, Iverson GL, Johnston KM, Kissick J, Kutcher J, Leddy JJ, Maddocks D, Makdissi M, Manley GT, McCrea M, Meehan WP, Nagahiro S, Patricios J, Putukian M, Schneider KJ, Sills A, Tator CH, Turner M, Vos PE. Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017 Jun;51(11):838-847. doi: 10.1136/bjsports-2017-097699. Epub 2017 Apr 26. No abstract available.
    Results Reference
    background
    PubMed Identifier
    15083870
    Citation
    Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, Kraus J, Coronado VG; WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004 Feb;(43 Suppl):28-60. doi: 10.1080/16501960410023732.
    Results Reference
    background
    PubMed Identifier
    31246881
    Citation
    Langer L, Levy C, Bayley M. Increasing Incidence of Concussion: True Epidemic or Better Recognition? J Head Trauma Rehabil. 2020 Jan/Feb;35(1):E60-E66. doi: 10.1097/HTR.0000000000000503.
    Results Reference
    background
    PubMed Identifier
    28483928
    Citation
    Makdissi M, Schneider KJ, Feddermann-Demont N, Guskiewicz KM, Hinds S, Leddy JJ, McCrea M, Turner M, Johnston KM. Approach to investigation and treatment of persistent symptoms following sport-related concussion: a systematic review. Br J Sports Med. 2017 Jun;51(12):958-968. doi: 10.1136/bjsports-2016-097470. Epub 2017 May 8.
    Results Reference
    background
    PubMed Identifier
    25801547
    Citation
    Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancet Neurol. 2015 May;14(5):506-17. doi: 10.1016/S1474-4422(15)00002-2. Epub 2015 Mar 20.
    Results Reference
    background
    PubMed Identifier
    33087373
    Citation
    Fallesen P, Campos B. Effect of concussion on salary and employment: a population-based event time study using a quasi-experimental design. BMJ Open. 2020 Oct 21;10(10):e038161. doi: 10.1136/bmjopen-2020-038161.
    Results Reference
    background
    PubMed Identifier
    28615996
    Citation
    Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017.
    Results Reference
    background
    PubMed Identifier
    30820754
    Citation
    Romeu-Mejia R, Giza CC, Goldman JT. Concussion Pathophysiology and Injury Biomechanics. Curr Rev Musculoskelet Med. 2019 Jun;12(2):105-116. doi: 10.1007/s12178-019-09536-8.
    Results Reference
    background
    PubMed Identifier
    33572884
    Citation
    Kreider RB, Stout JR. Creatine in Health and Disease. Nutrients. 2021 Jan 29;13(2):447. doi: 10.3390/nu13020447.
    Results Reference
    background
    PubMed Identifier
    25664170
    Citation
    Smith RN, Agharkar AS, Gonzales EB. A review of creatine supplementation in age-related diseases: more than a supplement for athletes. F1000Res. 2014 Sep 15;3:222. doi: 10.12688/f1000research.5218.1. eCollection 2014.
    Results Reference
    background
    PubMed Identifier
    25159005
    Citation
    Lowe MT, Faull RL, Christie DL, Waldvogel HJ. Distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine transporter immunoreactivity. J Comp Neurol. 2015 Apr 1;523(5):699-725. doi: 10.1002/cne.23667. Epub 2014 Sep 12.
    Results Reference
    background
    PubMed Identifier
    8889843
    Citation
    Whyte MP, Chines A, Silva DP Jr, Landt Y, Ladenson JH. Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res. 1996 Oct;11(10):1438-43. doi: 10.1002/jbmr.5650111010.
    Results Reference
    background
    PubMed Identifier
    33578876
    Citation
    Roschel H, Gualano B, Ostojic SM, Rawson ES. Creatine Supplementation and Brain Health. Nutrients. 2021 Feb 10;13(2):586. doi: 10.3390/nu13020586.
    Results Reference
    background
    PubMed Identifier
    26861125
    Citation
    Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between brain cells: What can be learned from human creatine deficiencies and various experimental models? Amino Acids. 2016 Aug;48(8):1877-95. doi: 10.1007/s00726-016-2189-0. Epub 2016 Feb 10.
    Results Reference
    background
    PubMed Identifier
    16520236
    Citation
    Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006 Mar 1;40(5):837-49. doi: 10.1016/j.freeradbiomed.2005.10.035. Epub 2005 Nov 2.
    Results Reference
    background
    PubMed Identifier
    9315696
    Citation
    O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 1997 Sep 8;414(2):253-7. doi: 10.1016/s0014-5793(97)01045-4.
    Results Reference
    background
    PubMed Identifier
    11985880
    Citation
    Watanabe A, Kato N, Kato T. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Neurosci Res. 2002 Apr;42(4):279-85. doi: 10.1016/s0168-0102(02)00007-x.
    Results Reference
    background
    PubMed Identifier
    14561278
    Citation
    Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc Biol Sci. 2003 Oct 22;270(1529):2147-50. doi: 10.1098/rspb.2003.2492.
    Results Reference
    background
    PubMed Identifier
    29704637
    Citation
    Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials. Exp Gerontol. 2018 Jul 15;108:166-173. doi: 10.1016/j.exger.2018.04.013. Epub 2018 Apr 25.
    Results Reference
    background
    PubMed Identifier
    32066709
    Citation
    Bakian AV, Huber RS, Scholl L, Renshaw PF, Kondo D. Dietary creatine intake and depression risk among U.S. adults. Transl Psychiatry. 2020 Feb 3;10(1):52. doi: 10.1038/s41398-020-0741-x.
    Results Reference
    background
    PubMed Identifier
    26748651
    Citation
    Bender A, Klopstock T. Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids. 2016 Aug;48(8):1929-40. doi: 10.1007/s00726-015-2165-0. Epub 2016 Jan 9.
    Results Reference
    background
    PubMed Identifier
    10491602
    Citation
    Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post-adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999 Oct;2(10):859-61. doi: 10.1038/13154. No abstract available.
    Results Reference
    background
    PubMed Identifier
    19699416
    Citation
    Johnson SB, Blum RW, Giedd JN. Adolescent maturity and the brain: the promise and pitfalls of neuroscience research in adolescent health policy. J Adolesc Health. 2009 Sep;45(3):216-21. doi: 10.1016/j.jadohealth.2009.05.016.
    Results Reference
    background
    PubMed Identifier
    30283061
    Citation
    Westerstahl M, Jansson E, Barnekow-Bergkvist M, Aasa U. Longitudinal changes in physical capacity from adolescence to middle age in men and women. Sci Rep. 2018 Oct 3;8(1):14767. doi: 10.1038/s41598-018-33141-3.
    Results Reference
    background
    PubMed Identifier
    16461469
    Citation
    Peters R. Ageing and the brain. Postgrad Med J. 2006 Feb;82(964):84-8. doi: 10.1136/pgmj.2005.036665.
    Results Reference
    background
    PubMed Identifier
    8551320
    Citation
    King NS, Crawford S, Wenden FJ, Moss NE, Wade DT. The Rivermead Post Concussion Symptoms Questionnaire: a measure of symptoms commonly experienced after head injury and its reliability. J Neurol. 1995 Sep;242(9):587-92. doi: 10.1007/BF00868811.
    Results Reference
    background
    PubMed Identifier
    10484486
    Citation
    Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol. 1999 Sep;277(3):R698-704. doi: 10.1152/ajpregu.1999.277.3.R698.
    Results Reference
    background
    PubMed Identifier
    12850248
    Citation
    Lyoo IK, Kong SW, Sung SM, Hirashima F, Parow A, Hennen J, Cohen BM, Renshaw PF. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res. 2003 Jun 30;123(2):87-100. doi: 10.1016/s0925-4927(03)00046-5.
    Results Reference
    background
    PubMed Identifier
    33557850
    Citation
    Antonio J, Candow DG, Forbes SC, Gualano B, Jagim AR, Kreider RB, Rawson ES, Smith-Ryan AE, VanDusseldorp TA, Willoughby DS, Ziegenfuss TN. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? J Int Soc Sports Nutr. 2021 Feb 8;18(1):13. doi: 10.1186/s12970-021-00412-w.
    Results Reference
    background
    PubMed Identifier
    19773644
    Citation
    Ling J, Kritikos M, Tiplady B. Cognitive effects of creatine ethyl ester supplementation. Behav Pharmacol. 2009 Dec;20(8):673-9. doi: 10.1097/FBP.0b013e3283323c2a.
    Results Reference
    background
    PubMed Identifier
    30705232
    Citation
    Harmon KG, Clugston JR, Dec K, Hainline B, Herring S, Kane SF, Kontos AP, Leddy JJ, McCrea M, Poddar SK, Putukian M, Wilson JC, Roberts WO. American Medical Society for Sports Medicine position statement on concussion in sport. Br J Sports Med. 2019 Feb;53(4):213-225. doi: 10.1136/bjsports-2018-100338.
    Results Reference
    background
    PubMed Identifier
    21143598
    Citation
    Belanger M, Allaman I, Magistretti PJ. Differential effects of pro- and anti-inflammatory cytokines alone or in combinations on the metabolic profile of astrocytes. J Neurochem. 2011 Feb;116(4):564-76. doi: 10.1111/j.1471-4159.2010.07135.x. Epub 2011 Jan 19.
    Results Reference
    background
    PubMed Identifier
    34223531
    Citation
    Balalla S, Krageloh C, Medvedev O, Siegert R. Is the Rivermead Post-Concussion Symptoms Questionnaire a Reliable and Valid Measure to Assess Long-Term Symptoms in Traumatic Brain Injury and Orthopedic Injury Patients? A Novel Investigation Using Rasch Analysis. Neurotrauma Rep. 2020 Aug 11;1(1):63-72. doi: 10.1089/neur.2020.0017. eCollection 2020.
    Results Reference
    background
    PubMed Identifier
    16323387
    Citation
    Eyres S, Carey A, Gilworth G, Neumann V, Tennant A. Construct validity and reliability of the Rivermead Post-Concussion Symptoms Questionnaire. Clin Rehabil. 2005 Dec;19(8):878-87. doi: 10.1191/0269215505cr905oa.
    Results Reference
    background

    Learn more about this trial

    The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms

    We'll reach out to this number within 24 hrs